Peer-Reviewed Study Validates First Blood Test for Early-Stage Breast Cancer Detection
Published study reports >92% sensitivity and specificity, outperforming current standards for supplemental screening SAINT PAUL, Minn., July 30, 2026 /PRNewswire/ -- Astrin Biosciences, a cancer intelligence company transforming how cancer is detected and treated through deep proteomics...
Published study reports >92% sensitivity and specificity, outperforming current standards for supplemental screening SAINT PAUL, Minn., July 30, 2026 /PRNewswire/ -- Astrin Biosciences, a cancer intelligence company transforming how cancer is detected and treated through deep proteomics...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.